Sign In
Buy BIIB
$196.45
+0.490 (+0.250%)
At Close: Jun 04, 2026
Does This Signal Trouble for Biogen's New Alzheimer's Drug?
05:30am, Monday, 19'th Jun 2023
Some European Alzheimer's experts are wary about the future of Biogen's drug Leqembi in the region. Regulators in Europe, the U.S., and Japan currently are reviewing the drug.
2 Market-Beating Stocks With Major Catalysts on the Way
10:07am, Saturday, 17'th Jun 2023
Vertex's next blockbuster could generate billions of dollars in sales. Biogen is inching closer to a goal it's been working on for a long time.
7 Undervalued S&P 500 Stocks to Buy in June
09:35pm, Thursday, 15'th Jun 2023
When attempting to build a portfolio of reliable entities, you probably can't go wrong with undervalued S&P 500 stocks. Featuring the market performance of 500 of the largest companies listed on stock
What's Happening With Biogen Stock?
08:00am, Wednesday, 14'th Jun 2023
After a 13% rise in Biogen stock (NASDAQ: BIIB) this year, aligning with the broader S&P500 index returns, we believe it has little room for growth.
Biogen has been an 'uninvestable' stock for awhile, says Mizuho's Jared Holz
06:36pm, Tuesday, 13'th Jun 2023
Jared Holz, Mizuho Securities healthcare sector specialist, joins 'Fast Money' to talk controversy brewing at Biogen, Alzheimer's drug approval roadblocks in Europe, and more.
Markets Rise Midday as Inflation News Raises Expectations of a Rate Hike Pause
12:25pm, Tuesday, 13'th Jun 2023
U.S. equities gained at midday on Tuesday, June 13, 2023 as lower inflation raised optimism the Fed could pause its rate hike cycle.
European Alzheimer's experts unconvinced by new Eisai, Biogen drug
03:16am, Tuesday, 13'th Jun 2023
Alzheimer's disease experts in Europe weighing potential use of a new drug from Eisai and Biogen say its ability to slow cognitive decline may not outweigh its health risks, or be worth the toll on sc
3-Stock Lunch: Oracle, Biogen and SentinelOne
03:25pm, Monday, 12'th Jun 2023
Eva Ados, ERShares chief operations officer, joins ‘Power Lunch' to discuss three stocks: Oracle, Biogen and SentinelOne.
BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing
10:47am, Monday, 12'th Jun 2023
Biogen (NASDAQ: BIIB ) stock is a hot topic among traders on Monday as the company's share resumed trading following a halt that was in effect on Friday. With that halt coming to an end, investors in
Biogen (BIIB), Eisai Alzheimer Drug Gets FDA Panel Endorsement
10:28am, Monday, 12'th Jun 2023
An FDA advisory committee supports granting full approval to Biogen (BIIB)/Eisai's Alzheimer's disease antibody. NASDAQ halts BIIB's common stock trading on Jun 9.
Biogen shares rise on imminent approval of Alzheimer's drug following FDA panel vote
08:46am, Monday, 12'th Jun 2023
Biogen Inc (NASDAQ:BIIB) shares rose in pre-market trading on Monday after a Food and Drug Administration (FDA) panel voted in favor of Eisai and Biogen's drug LEQEMBI as a treatment for Alzheimer's d
5 Things to Know Before Markets Open
07:35am, Monday, 12'th Jun 2023
UBS completes its takeover of Credit Suisse and Biogen wins key FDA support for its Alzheimer's disease treatment. Here's what investors need to know today.
Biogen rises as FDA panel backs Alzheimer's drug, easing safety concerns
06:26am, Monday, 12'th Jun 2023
Shares of Biogen Inc rose 4% in premarket trade on Monday as an unanimous backing of the company's Alzheimer's drug Leqembi by the U.S. regulator's advisers eased concerns that a traditional approval
Biogen stock climbs on drug approval recommendation, Oracle shares rise ahead of earnings, and other stocks on the move
05:38am, Monday, 12'th Jun 2023
Biogen Inc. shares BIIB, +1.31% rallied 5% following a full-day halt during the regular session as a Food and Drug Administration committee convened to vote on an approval recommendation for the biote
Biogen inches closer to FDA approval for its Alzheimer's drug
02:33pm, Saturday, 10'th Jun 2023
Shares of Biogen Inc (NASDAQ: BIIB) gained nearly 10% in extended hours after the biotech firm edged closer to winning FDA approval for its Alzheimer's drug. FDA panel greenlights Biogen's Leqembi Lat
